Development of Validated Stability Indicating HPTLC Method for the Estimation of Teriflunomide in Bulk and Tablet Dosage Form
暂无分享,去创建一个
[1] Sarfaraz K. Niazi. Stability Testing: Photostability Testing of New Drug Substances and Products , 2019, Handbook of Pharmaceutical Manufacturing Formulations.
[2] Nukendra Prasad Nadella,et al. Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in-vitro dissolution , 2017 .
[3] Sarfaraz Niazi,et al. Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.
[4] P. Riccio,et al. Nutrition Facts in Multiple Sclerosis , 2015, ASN neuro.
[5] B. Saini,et al. Isolation and characterization of a degradation product in leflunomide and a validated selective stability-indicating HPLC–UV method for their quantification , 2014, Journal of pharmaceutical analysis.
[6] M. Freedman. Teriflunomide in relapsing multiple sclerosis: therapeutic utility , 2013, Therapeutic advances in chronic disease.
[7] T. Rozek,et al. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. , 2011, Journal of pharmaceutical and biomedical analysis.
[8] J. Marriott,et al. Emerging therapies in relapsing-remitting multiple sclerosis. , 2010, Reviews on recent clinical trials.
[9] P. Shrivastav,et al. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[10] H. Hartung,et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis , 2009, Neuropsychiatric disease and treatment.